| Literature DB >> 33197228 |
Tarek M El-Achkar1, Michael T Eadon1, Rajasree Menon2, Blue B Lake3, Tara K Sigdel4, Theodore Alexandrov5, Samir Parikh6, Guanshi Zhang7, Dejan Dobi4, Kenneth W Dunn1, Edgar A Otto2, Christopher R Anderton7,8, Jonas M Carson9, Jinghui Luo2, Chris Park9, Habib Hamidi2, Jian Zhou10,11, Paul Hoover12, Andrew Schroeder4, Marianinha Joanes4, Evren U Azeloglu13, Rachel Sealfon10,11, Seth Winfree1, Becky Steck2, Yongqun He2, Vivette D'Agati11, Ravi Iyengar13, Olga G Troyanskaya10,11, Laura Barisoni14, Joseph Gaut15, Kun Zhang3, Zoltan Laszik4, Brad H Rovin6, Pierre C Dagher1, Kumar Sharma7, Minnie M Sarwal4, Jeffrey B Hodgin2, Charles E Alpers9, Matthias Kretzler2, Sanjay Jain15.
Abstract
Comprehensive and spatially mapped molecular atlases of organs at a cellular level are a critical resource to gain insights into pathogenic mechanisms and personalized therapies for diseases. The Kidney Precision Medicine Project (KPMP) is an endeavor to generate three-dimensional (3-D) molecular atlases of healthy and diseased kidney biopsies by using multiple state-of-the-art omics and imaging technologies across several institutions. Obtaining rigorous and reproducible results from disparate methods and at different sites to interrogate biomolecules at a single-cell level or in 3-D space is a significant challenge that can be a futile exercise if not well controlled. We describe a "follow the tissue" pipeline for generating a reliable and authentic single-cell/region 3-D molecular atlas of human adult kidney. Our approach emphasizes quality assurance, quality control, validation, and harmonization across different omics and imaging technologies from sample procurement, processing, storage, shipping to data generation, analysis, and sharing. We established benchmarks for quality control, rigor, reproducibility, and feasibility across multiple technologies through a pilot experiment using common source tissue that was processed and analyzed at different institutions and different technologies. A peer review system was established to critically review quality control measures and the reproducibility of data generated by each technology before their being approved to interrogate clinical biopsy specimens. The process established economizes the use of valuable biopsy tissue for multiomics and imaging analysis with stringent quality control to ensure rigor and reproducibility of results and serves as a model for precision medicine projects across laboratories, institutions and consortia.Entities:
Keywords: imaging; kidney disease; metabolomics; proteomics; transcriptomics
Mesh:
Year: 2020 PMID: 33197228 PMCID: PMC7847045 DOI: 10.1152/physiolgenomics.00104.2020
Source DB: PubMed Journal: Physiol Genomics ISSN: 1094-8341 Impact factor: 3.107